228 related articles for article (PubMed ID: 36910075)
1. Relationship between valvular structure and biochemical indices of non-valvular atrial fibrillation and senile degenerative valvular heart disease.
Chen JQ; Zeng X; Li KC; Huang JL; Guo BL; Zhou X
J Thorac Dis; 2023 Feb; 15(2):611-619. PubMed ID: 36910075
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
Owens RE; Kabra R; Oliphant CS
Clin Cardiol; 2017 Jun; 40(6):407-412. PubMed ID: 28004413
[TBL] [Abstract][Full Text] [Related]
3. Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation - The Fushimi AF Registry.
Doi K; Ogawa H; Ishigami K; Ikeda S; Aono Y; Hamatani Y; Fujino A; An Y; Ishii M; Iguchi M; Masunaga N; Esato M; Tsuji H; Wada H; Hasegawa K; Abe M; Akao M;
Circ J; 2020 Apr; 84(5):714-722. PubMed ID: 32213725
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
Thomas KL; Jackson LR; Shrader P; Ansell J; Fonarow GC; Gersh B; Kowey PR; Mahaffey KW; Singer DE; Thomas L; Piccini JP; Peterson ED
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29273635
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Prognosis of Patients With Nonvalvular Atrial Fibrillation and Significant Valvular Heart Disease Referred for Electrical Cardioversion.
Vo NM; Leung M; van Rosendael PJ; Goedemans L; van Wijngaarden SE; Prihadi EA; van der Bijl P; Ajmone Marsan N; Delgado V; Bax JJ
Am J Cardiol; 2020 Aug; 128():84-91. PubMed ID: 32650929
[TBL] [Abstract][Full Text] [Related]
7. Distribution, Characteristics, and Management of Older Patients With Valvular Heart Disease in China: China-DVD Study.
Xu H; Liu Q; Cao K; Ye Y; Zhang B; Li Z; Hao J; Qi X; Zhao Q; Liu S; Gao R; Wu Y;
JACC Asia; 2022 Jun; 2(3):354-365. PubMed ID: 36338396
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation.
Samaras A; Vrana E; Kartas A; Moysidis DV; Papazoglou AS; Doundoulakis I; Fotos G; Rampidis G; Tsalikakis DG; Efthimiadis G; Karvounis H; Tzikas A; Giannakoulas G
BMC Cardiovasc Disord; 2021 Sep; 21(1):453. PubMed ID: 34536990
[TBL] [Abstract][Full Text] [Related]
9. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
10. Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study.
Başaran Ö; Dogan V; Beton O; Tekinalp M; Aykan AÇ; Kalaycıoğlu E; Bolat I; Taşar O; Şafak Ö; Kalçık M; Yaman M; İnci S; Altıntaş B; Kalkan S; Kırma C; Biteker M;
J Thromb Thrombolysis; 2017 Feb; 43(2):157-165. PubMed ID: 27848065
[TBL] [Abstract][Full Text] [Related]
11. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank.
Tung M; Nah G; Tang J; Marcus G; Delling FN
Open Heart; 2022 Sep; 9(2):. PubMed ID: 36104095
[TBL] [Abstract][Full Text] [Related]
12. [The best of valvular heart disease in 2006].
de Gevigney G;
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():19-28. PubMed ID: 17405561
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Mitral and Aortic Valvular Disease and Left Ventricular Dysfunction in a Lebanese Population: Retrospective Single-Center Experience.
Nader V; Matta A; Canitrot R; Itier R; Salameh P; Lairez O; Elbaz M; Galinier M; Azar R; Roncalli J
Med Sci Monit; 2021 Feb; 27():e928218. PubMed ID: 33558450
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease.
Hojo Y; Kumakura H; Kanai H; Iwasaki T; Ichikawa S; Kurabayashi M
Eur Heart J Cardiovasc Imaging; 2016 May; 17(5):492-7. PubMed ID: 26758409
[TBL] [Abstract][Full Text] [Related]
15. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
[TBL] [Abstract][Full Text] [Related]
16. Assessing left atrial function in patients with atrial fibrillation and valvular heart disease using cardiovascular magnetic resonance imaging.
Hou J; Sun Y; Zhang L; Wang W; You H; Zhang R; Yang B; Wang H
Clin Cardiol; 2022 May; 45(5):527-535. PubMed ID: 35289415
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease.
Vinereanu D; Wang A; Mulder H; Lopes RD; Jansky P; Lewis BS; Gersh BJ; Avezum A; Hanna M; Held C; Wallentin L; Granger CB; Alexander JH
Heart; 2018 Aug; 104(15):1292-1299. PubMed ID: 29352007
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey.
Iung B; Delgado V; Rosenhek R; Price S; Prendergast B; Wendler O; De Bonis M; Tribouilloy C; Evangelista A; Bogachev-Prokophiev A; Apor A; Ince H; Laroche C; Popescu BA; Piérard L; Haude M; Hindricks G; Ruschitzka F; Windecker S; Bax JJ; Maggioni A; Vahanian A;
Circulation; 2019 Oct; 140(14):1156-1169. PubMed ID: 31510787
[TBL] [Abstract][Full Text] [Related]
19. Profiles of hospitalized patients with valvular heart disease: Experience of a tertiary center.
Esteves AF; Brito D; Rigueira J; Ricardo I; Pires R; Pedro MM; Veiga F; Pinto F
Rev Port Cardiol (Engl Ed); 2018 Dec; 37(12):991-998. PubMed ID: 30554887
[TBL] [Abstract][Full Text] [Related]
20. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
Di Pasquale G; Zagnoni S; Riva L
Intern Emerg Med; 2015 Feb; 10(1):21-4. PubMed ID: 25589164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
